MX9705281A - Formulaciones de acetaminofen de alta carga, compresible directamente. - Google Patents
Formulaciones de acetaminofen de alta carga, compresible directamente.Info
- Publication number
- MX9705281A MX9705281A MX9705281A MX9705281A MX9705281A MX 9705281 A MX9705281 A MX 9705281A MX 9705281 A MX9705281 A MX 9705281A MX 9705281 A MX9705281 A MX 9705281A MX 9705281 A MX9705281 A MX 9705281A
- Authority
- MX
- Mexico
- Prior art keywords
- acetaminophen
- percent
- weight
- dosage forms
- direct compression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se presentan las formas de dosis farmacéuticas solidas, de compresion directa que contienen: a) desde aproximadamente 40 hasta aproximadamente 95% por peso de acetaminofen; b) desde aproximadamente 1 hasta aproximadamente 60% por peso de un vehículo de compresion directa que comprende celulosa microcristalina; y c) desde aproximadamente 0.01 hasta aproximadamente 4.0% por peso de un lubricante farmacéuticamente aceptable. el acetaminofen y el vehículo de compresion directa se combina bajo condiciones de alta cizalla que son suficientes para transformar la acetaminofen y el vehículo de compresion directa en un granulado homogéneo sin degradacion. En los aspectos preferidos de la invencion, el lubricante también se combina con el acetaminofen y el vehículo de compresion directa bajo condiciones de alta cizalla. También se presentan los métodos de preparacion de las formas de dosis solidas farmacéuticas, comprimidas directamente y los métodos de tratamiento con las formas de dosis. Los métodos son particularmente adecuados para preparar las formas de dosis comprimidas directamente que contengan cantidades de carga alta (es decir hasta 80% o mayor) de acetaminofen basado en el peso total de la tableta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/558,335 US5733578A (en) | 1995-11-15 | 1995-11-15 | Directly compressible high load acetaminophen formulations |
| US08558335 | 1995-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9705281A true MX9705281A (es) | 1998-06-30 |
| MXPA97005281A MXPA97005281A (es) | 1998-10-30 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| EP0805675A4 (en) | 2000-10-04 |
| AU1123997A (en) | 1997-06-05 |
| JP3334885B2 (ja) | 2002-10-15 |
| JP2002060338A (ja) | 2002-02-26 |
| CA2208322A1 (en) | 1997-05-22 |
| EA199700110A1 (ru) | 1997-12-30 |
| WO1997017947A1 (en) | 1997-05-22 |
| NO973123D0 (no) | 1997-07-04 |
| NO973123L (no) | 1997-08-14 |
| EA000223B1 (ru) | 1998-12-24 |
| CN1168094A (zh) | 1997-12-17 |
| US6217907B1 (en) | 2001-04-17 |
| CA2208322C (en) | 2004-01-20 |
| EP0805675A1 (en) | 1997-11-12 |
| AU709212B2 (en) | 1999-08-26 |
| US5965166A (en) | 1999-10-12 |
| KR100236326B1 (ko) | 1999-12-15 |
| US5733578A (en) | 1998-03-31 |
| TW518237B (en) | 2003-01-21 |
| BR9607710A (pt) | 1999-01-05 |
| JPH10506412A (ja) | 1998-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2208322A1 (en) | Directly compressible high load acetaminophen formulations | |
| FI20011851A (fi) | Fluoksetiinia tai sen happoadditiosuolaa sisältävä dispergoituva tabletti | |
| AU7655194A (en) | Active principles and gas containing microparticles | |
| CA2265766A1 (en) | Rapidly disintegrating pellets | |
| RU2008143545A (ru) | Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2 | |
| AP0202540A0 (en) | Inhibitors of interleukin -1B converting enyme. | |
| DK0881899T3 (da) | Ibuprofen-doseringsform | |
| EA199800936A1 (ru) | Грануляты гидролизованной целлюлозы для фармацевтических препаратов | |
| FI953442A (fi) | Gonadotropiinia sisältäviä pakastekuivattuja pallosia | |
| MY128046A (en) | Rapidly disintegrating methylcellulose tablets | |
| HK1073263A1 (en) | A process for the preparation of tablets from pharmaceutically active substances having unfavourabletabletting properties with a granulating liquid c omprising microcrystalline cellulose | |
| YU19301A (sh) | Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze | |
| DE69428897D1 (de) | Enzymtablette und Verfahren zu deren Herstellung | |
| AU4310097A (en) | Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists | |
| AU4627096A (en) | Pharmaceutical compositions in the form of slow release tablets based on high molecular weight polysaccharide granules | |
| MY110014A (en) | Psyllium-containing products. | |
| BR9504573A (pt) | Formulaçao farmaceutica adequada para fabricaçao de tabletes dispersiveis por compressao direta tablete de cefaclor dispersivel e processo para fabricaçao de um tablete dispersivel contendo cefaclor | |
| PH31320A (en) | Fenbendazole formulations. | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| NZ324674A (en) | Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant | |
| UA74388C2 (uk) | Фармацевтичні композиції тизоксаніду і нітазоксаніду | |
| BG102638A (en) | Tablets having increased phamcyclovir content | |
| IES950586A2 (en) | Pharmaceutical processing | |
| MD1218G2 (ro) | Agent antimutagen | |
| MX9805015A (es) | INHIBIDORES DE LA ENZIMA QUE CONVIERTE LA INTERLEUCINA-1 beta. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| MM | Annulment or lapse due to non-payment of fees |